KURA ONCOLOGY INC (KURA)
Health Care · NASDAQ
Kura Oncology is a clinical-stage biopharmaceutical company developing and commercializing oncology therapies.
What KURA ONCOLOGY INC does
Kura Oncology is a clinical-stage biopharmaceutical company developing and commercializing oncology therapies. The company has commercialized KOMZIFTI (tipifarnib), an oral farnesyltransferase inhibitor, and maintains a pipeline of product candidates in development. Kura generates revenue from product sales and collaboration agreements, including a license agreement with Kyowa Kirin for development and commercialization rights.
Themes: ["Oncology / cancer therapeutics","Commercially-stage biopharmaceutical","Rare / orphan oncology indications"]
Fundamentals
- Price$12.08 as of 2026-07-09 close
- Market cap$1.1B as of 2026-07-10
- 1-year return+96.1% as of 2026-07-09 close
- Net margin-411.2% as of 2026-07-10
- Gross margin+99.9% as of 2026-07-10
- ROE-141.9% as of 2026-07-10
- Debt / equity0.09 as of 2026-07-10
- Revenue growth (YoY)+29.5% as of 2026-07-10
- Beta0.36 as of 2026-07-10
Key risks (from latest filing)
["Dependence on successful commercialization of KOMZIFTI; limited market acceptance or uptake could significantly impact revenues and financial viability","Competition from established and emerging oncology therapies; success of competing drugs could erode market share and pricing","Regulatory risk; loss of regulatory approval, product holds, or label restrictions for KOMZIFTI or pipeline candidates could impair commercialization and revenue generation"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.